Skip to content
DataLookout
Menu

NCT07723963

A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy

StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Site details revised at 1 of 23 sites
  2. Minor Trial sites expanded: 19 → 23 locations
  3. Notable Recruitment opened
    • Eligibility criteria expanded, about 12 words
    • Study sites: 19 to 20
    • Secondary endpoints: details revised at 1 of 9 entries
  4. Minor Trial sites expanded: 10 → 19 locations
    • Start date: Sep 1, 2026 to Sep 18, 2026
    v3
  5. Minor Study title shortened, about 6 wordsv2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change from baseline in myoclonic seizure days per 28 days (Part A and Part B)
Timeframe: Baseline up to end of 16 weeks treatment period

Secondary (9)

Patient and Caregiver Global Impression of Change in Usual Daily Activities (P/CaGI-C UDA) (Part A and Part B)
Proportion of participants who achieve ≥ 50% and ≥ 75% reduction from baseline in myoclonic seizure days (Part A and Part B)
Change from baseline in days with any seizure type per 28 days (Part A and Part B)
Number of days with fewer myoclonic seizures than participant average prior to entering the study per 28 days (Part A and Part B)
Percent change from baseline (historical + prospective) in generalized tonic-clonic (GTC) seizure frequency (Part A and Part B)
Show 4 moreShow less
Number of participants reporting treatment-emergent adverse events (Part A and Part B)
Mean plasma concentration for CBD
Mean plasma concentration of metabolite 7-OH-CBD
Mean plasma concentration of metabolite 7-COOH-CBD

Arms and interventions

JZP926 CapsuleExperimental

Participants with JME will be randomized to JZP926 capsule based on weight-tiered dosing for a 16-week treatment period.

PlaceboPlacebo comparator

Participants with JME will be randomized to matching placebo based on weight-tiered dosing for a 16-week treatment period.

Open-Label Extension: JZP926 CapsuleExperimental

Participants completing Part A or Part B will have the option to continue into an open-label extension for up to 52 weeks, inclusive of a 4 week blinded transition.

Drugs: JZP926 capsule, Placebo

Sites

23 sites in 1 country